possible differentials. We have learnt the importance of retaining a high index of suspicion when faced with patients presenting with neurological signs and symptoms particularly when there is an absence of significant systemic disease and which important investigations are required to achieve the correct diagnosis. The key learning objective is to highlight PACNS as a possible differential in patients with neurological involvement where vasculitis is a diagnostic consideration but where there is an absence of systemic features one would normally expect to find. Further objectives include reviewing the different ways PACNS can present itself clinically and radiologically and if the diagnosis is in doubt to follow a series of investigations which may lead one to the gold standard that is brain biopsy. Finally, this case shows certain findings that are common to PACNS for example lack of ESR/CRP response, lymphopaenia, lymphocytic CSF with mildly elevated protein and positive oligoclonal bands which are absent in serum and non-specific white matter changes on brain imaging. These findings may help to point towards a diagnosis of PACNS and are important for the rheumatologist to be aware of when investigating patients with possible vasculitis and neurological involvement. Introduction: We present a case of a gentleman with a new diagnosis of intracranial plasma cell myeloma. PET scan as part of work-up identified the incidental presence of increased uptake primarily of the large vessel arterial system consistent with vasculitis. Review of the literature describes association of vasculitis and haematological malignancy (such as myelodysplastic syndrome and lymphoprolferative disorders), however the association with myeloma (and specifically large vessel vasculitis) appears to be less frequent with limited reported cases. We therefore wish to highlight this case for the interest of our rheumatological colleagues. Case description: A 71 year old gentleman presented acutely with worsening vertigo symptoms and associated nausea. He had been experiencing such symptoms over the preceding two months, with his condition gradually progressing overthattime.He hadbeenexperiencing intermittent right-sided occipital headaches, and following review from his GP during this period, he was started on gabapentin to manage a provisional diagnosis of occipital neuralgia. Apart from the above, he denied systemic features of weight loss, pyrexia, skin rash, myalgia or arthralgia. The patient had an extensive past medical history including monoclonal gammopathy of undetermined significance (IgG lambda paraprotein), IgG-mediatedperipheralneuropathy, postural hypotensionand previous diagnosis of polymyalgia rheumatica (in remission at time of presentation and not on therapy). Despite the above co-morbidities, prior to his recent symptoms, this gentleman was otherwise fit and well, and was only under observation in regards to his MGUS diagnosis via the local haematology team. On presentation, no obvious objective clinical abnormality could be identified including neurological deficit. GCS was 15/15. Routine blood tests were within normal range including inflammatory markers of CRP and ESR. In view of progressive vertigo symptoms, concerns of a possible intracranial lesion was considered, and as such arrangements were made for an urgent MRI head scan. This was reported to show an isointense, homogeneously enhancing destructive mass centred on the right occipital skull base, with a significant extraosseous component indenting the right cerebellar hemisphere with gross oedema. The lesion was approximately 6 cm in size. No hydrocephalus was present at time of the scan. Urgent neurosurgical opinion was advised and dexamethasone therapy (8 mg BD) was initiated. Neurosurgical review was arranged at the local centre, and biopsy of the lesion was performed. Histology demonstrated tissue diffusely infiltrated by plasma cells positive for CD138, CD79a and monotypic for lambda light chain -features were deemed consistent with plasma cell myeloma. Bone marrow trephine reported a small population of lambda light chain predominant plasma cells, confirmed by CD-138 potentially suggestive of myeloma. CT chest/abdomen/pelvis did not identify any obvious primary/secondary lesions. PET CT scan was arranged, which as well as the intrancranial lesion described, also reported generalised FDG uptake of the aorta, subclavian, axillary, common/external iliac and femoral arteries -findings were reported as consistent with large vessel vasculitis and were identified despite dexamethasone use. His case was referred to the haematology team for further management and decision has been made for radiotherapy treatment of the intracranial lesion. Incidental vasculitic changes described on PET scan have been attributed as secondary to his haematological condition, and arrangements are made for re-imaging following treatment. Discussion: Associations between malignancy and vasculitis have been previously reported within the literature, with approximately 5-8% of vasculitis cases having associated malignancy. Reports suggest that haematological malignancies are more commonly associated than organ solid tumours, with sub-types such as MDS and lymphoma being most prominent. Myeloma related vasculitis appears to be less common, with limited described case reports. Various theories are made regarding the link of malignancy and vasculitis, with cause and affect between the two being unclear. For example, one potential association with myeloma is the development IL-6 genes resulting in leucocytoclastic vasculitis (LCV). LCV has been reported among the most common vasculitides associated with malignancy, however this is usually associated with small vessel cutaneous vasculitis. Indeed, large vessel vasculitis (as suggested by this case) related to myeloma appears to be extremely rare based on limited reports available. As per our described case, the patientdid notappear tohave findingssuggestiveof systemicvasculitis, and despite apparent extensive vascular involvement as per PET imaging, inflammatory markers remained normal throughout the presentation (even prior to dexamethasone usage) and appears to be an incidental finding from imaging. As mentioned, our patient is currently undergoing treatment for his primary intracranial lesion under the haematology team. Following therapy, it would be interesting to review whether apparent PET findings settle once the primary myeloma is managed. Key Learning Points: The primary presentation for this patient focussed on his symptoms of persistent vertigo and associated nausea. Through extensive investigations involving multiple specialties, we were able to identify the causative lesion and histology suggestive of intracranial myeloma. Incidental finding of large vessel vasculitis on PET scan has highlighted a potential association between the two diagnoses. Myeloma and large vessel vasculitis appears to be rarely reported within the literature, andas suchwe feelthis particular case maybeofinteresttothe rheumatological community. Follow up on completion of myeloma treatment is planned to review possibleresolution of PET findings. Disclosure: S. El-Ghazali: None. K. Bhamra: None. A. Khan: None. M. Burden:None. V. Nallapuneni:None. I. Patel:None.
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